Essential medicines and health products

WHO prequalifies breakthrough vaccine for typhoid

At the end of December 2017, WHO prequalified the first conjugate vaccine for typhoid, Bharat Biotech’s Typbar-TCV®. Typhoid conjugate vaccines (TCVs) are innovative products that have longer-lasting immunity than older vaccines, require fewer doses, and can be given to young children through routine childhood immunization programs. The fact that the vaccine has been prequalified by WHO means that it meets acceptable standards of quality, safety and efficacy.
This makes the vaccine eligible for procurement by UN agencies, such as UNICEF, and Gavi, the Vaccine Alliance.

WHO prequalifies over 17 vector control products, paving way for increased control of malaria and other major vector-borne diseases

18 December 2017 - In the fastest ever prequalification process, WHO has assessed and listed 17 products for use in controlling vector borne diseases, including long lasting insecticidal bed nets, indoor residual sprays, space sprays, larvicides and insecticide-treated net kits.

WHO recommends the most stringent level of international control for synthetic opioid carfentanil

WHO has this week endorsed a recommendation from the Expert Committee on Drug Dependence (ECDD) to include carfentanil, an analogue of the prescription opioid fentanyl, into Schedules I and IV of the 1961 UN Single Convention on Narcotic Drugs. Schedule I substances are subject to strict drug control measures. Additional control under Schedule IV imposes the strongest possible regulations on substances by prohibiting production and supply of substances except under licence for specific purposes, such as medical treatment and research. In the case of carfentanil, there is no indication for human use.

WHO advises Dengvaxia be used only in people previously infected with dengue

WHO

Following a consultation of the Global Advisory Committee on Vaccine Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but it should not be administered to people who have not previously been infected with dengue virus.

This recommendation is based on new evidence communicated by the vaccine’s manufacturer (Sanofi Pasteur), indicating an increase in incidence of hospitalization and severe illness in vaccinated children never infected with dengue.

1 in 10 medical products in developing countries is substandard or falsified
WHO urges governments to take action

Geneva, 28 November 2017: An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO). This means that people are taking medicines that fail to treat or prevent disease.

The WHO essential medicines and health products programme works to increase access to essential, high-quality, safe, effective and affordable medical products.